NewslettersHuman Immunology NewsImmune Regulation NewsIntestinal Cell NewsSurrozen Initiates Dosing in Phase I Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative ColitisBy Danielle Corrigan - May 19, 2022067Surrozen, Inc. announced that the first subject has been dosed in its three-part Phase I clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.[Surrozen, Inc.]Press Release